



Esam Z. Dajani, Ph.D., FACG

President, IDDC Corporation

Adjunct Professor of Medicine, Loyola University-Chicago
1549 RFD, Long Grove, Illinois 60047-9532

Phone: (847) 634-9586; (847) 971-7555 (Cell)

E-mail: EsamD@comcast.net; Esam.Dajani@gmail.com

Web site: www.EsamDajani.wordpress.com

- Areas of Expertise:** Clinical pharmacology, toxicology, drug development and regulatory affairs. Professor Dajani provides scientific consulting services to pharmaceutical companies, governmental agencies and investment organizations. He also provides litigation support and testimony for plaintiff and defense attorneys in the fields of pharmaceutical patent litigations, Contract Research Organizations (CROs), drug injury causation, drug-related medical malpractice, medication errors, drug product liability, forensic aspects of alcohol intoxication and psychotropic drugs. He provides investigations, research, record analysis, consultation, merit statement, and testimony.
- Professional Experience:** Provided scientific consultation, advice and litigation support since 1993. Over 40 years experience in pharmaceutical research and development. Founder and President of IDDC Corporation, a CRO, which provides scientific consulting services for pharmaceutical companies, law firms and governmental agencies. Directed worldwide clinical research and development at major pharmaceutical companies. Led the research teams that discovered and developed misoprostol (Cytotec®) an anti-ulcer drug. Taught pharmacology and toxicology to medical, dental and pharmacy students. Licensed to practice pharmacy in the State of Alabama.
- Education:** B.S. in Pharmacy, University of Missouri at Kansas City, 1963.
M.S. in Pharmacology & Medicinal Chemistry, Auburn University, 1966.
Ph.D. in Pharmacology & Toxicology, Purdue University, 1969.
- Publications/ Presentations:** 130 peer-reviewed biomedical articles, book chapters and patents.
130 presentations at national and international biomedical conferences.
- Teaching Experience:** Adjunct Professor of Medicine, Loyola University Chicago, 1995-present.
Adjunct Professor of Pharmacology, Chicago Medical School, 1983-1990.
Adjunct Associate Professor of Pharmacology, Northwestern University, 1980-1995.
- Honors:** Won the Edgar M. Queeny Award (Monsanto Corporation) for distinguished achievements.
Won the Distinguished Alumnus Award from Purdue University for outstanding scientific contributions.

Positions Held:

President and Founder of International Drug Development Consultants (IDDC) Corporation, Long Grove, Illinois. 1993-Present. IDDC Corporation is a CRO which provides drug development, scientific consulting and litigation support services. The consulting services cover clinical research, pharmacology, toxicology, regulatory affairs, drug development and pharmaceutical patents. The litigation support and testimony services cover the fields of drug injury causation, drug-related medical malpractice, medication errors, drug product liability (e.g., warnings, designs, formulations, labeling), pharmaceutical patent litigations, adverse effects of health and beauty products, alcohol and industrial chemicals, forensic aspects of alcohol and psychotropic drugs and CROs activities.

Director, Clinical Research, G.D. Searle and Co., Skokie, Illinois. 1987-1993. Directed worldwide clinical research and development (Phases I-IV). Provided consultation services and actively interacted with clinical, regulatory affairs, legal, marketing, business development and licensing groups.

Director, Cytotec Scientific and Medical Affairs, G.D. Searle and Co., Skokie, Illinois. 1985-1986. Directed Phase-IV clinical research activities with misoprostol (Cytotec®). Assisted in the worldwide launch of misoprostol. Provided consultation services and actively interacted with clinical, regulatory affairs, sales and marketing, business development, licensing, legal groups and worldwide medical communications.

Assistant/Associate Director, Gastroenterology Clinical Research, G.D. Searle and Co., Skokie, Illinois. 1980-1985. Responsibilities included development of clinical plans, budgets, writing protocols, study placements, monitoring and preparation of clinical and regulatory reports. Interacted with clinical, regulatory affairs, consumer products, marketing, business development and licensing groups.

Chairman, Gastrointestinal Diseases Committee, G.D. Searle and Co., Skokie, Illinois. 1974-1980. Directed the research of a multi-disciplinary group (M.D./Ph.D. level scientists) which resulted in the discovery of several interesting drugs. Of these, one drug (Cytotec®) was marketed. Actively interacted with clinical, regulatory affairs, legal (patents), consumer products and business groups (marketing, sales, licensing and product acquisition).

Group Leader, Department of Pharmacology, G.D. Searle and Co., Skokie, Illinois. 1974-1980. Planned, conducted and directed research in gastrointestinal pharmacology and physiology.

Senior Research Investigator, G.D. Searle and Co., Skokie, Illinois. 1972-1974. Planned, conducted and directed research in gastrointestinal pharmacology and physiology.

Senior Pharmacologist, Rohm and Hass Research Laboratories, Spring House, Pennsylvania, 1968-1972. Directed and conducted research in gastrointestinal, cardiovascular and central nervous system pharmacology and toxicology.

Graduate Teaching Assistant: Auburn and Purdue Universities. 1964 to 1968. Taught pharmacy, pharmacology and toxicology to undergraduate pharmacy students.

Memberships in Scientific and Professional Societies:

American Society for Pharmacology and Experimental Therapeutics.
American Gastroenterological Association.
American College of Gastroenterology (Fellow).
European Association for Gastroenterology and Endoscopy.
Association for Academic Minority Physicians (Board Member).
Society for Experimental Biology and Medicine.
American Federation for Clinical Research.
American Pharmaceutical Association.
Gastroenterology Research Group.
New York Academy of Sciences.
Chicago Society of Gastroenterology.
Philadelphia Gastrointestinal Research Forum.
Gastrointestinal Pharmacology Group.
Chicago Biotech Network (Founder).

Honors:

Won the prestigious Edgar M. Queeny Award (Monsanto, 1991) for distinguished achievements in science and business.
Won the 1991 Distinguished Alumnus Award from the Department of Pharmacology and Toxicology, Purdue University.
Rho Chi Pharmaceutical Honorary Fraternity.
Phi Kappa Phi Honorary Fraternity.
Listed in several Marquis Publications: Who's Who in Medicine and Healthcare, Who's Who in Science and Engineering, Who's Who in the World, Who's Who in Technology Today and Who's Who in the Midwest.
Listed in the American Men and Women of Science.

Professional Groups Activities:

Member of the National Research Mentoring Network (NRMN-NIH), to promote academic mentoring of biomedical scientists and physicians.
Appointed by the FDA to be a Special Government Employee to assist the agency in reviewing gastrointestinal drugs, 2006-2010.
Research Grant Reviewer for the Ministry of Education and Sciences of the Russian Federation 2011.
Academic Editor: British Journal of Pharmaceutical Research, Science Domain International. 2012-present.
Academic Editor: Journal of Advances in Medical and Pharmaceutical Sciences. Science Domain International. 2013-present.
Academic Editor: The Scientific World Journal (Gastroenterology), 2010-present.
Academic Editor: WebMed Central, 2012-Present.
Associate Editor: Medical Science Monitor, 2003-2010.
Associate Editor: Progress in Medical Research, 2004-2010.
Sessions Chairman or Co-Chairman, Association for Academic Minority Physicians Annual Meetings, 1991-2016.
Session Co-Chairman and Guest Editor, Second International Symposium on Brain-Gut Axis, Krakow, Poland, 2003.

Scientific Director, Second International Symposium on Gastroenterology, Osaka, Japan, 1993.

Chairman, Pharmaceutical Industry Perspectives in the Discovery and Development of Antiulcer Drugs. Second International Symposium on Experimental and New Therapeutic Approaches to Ulcer Disease. Pecs, Hungary, July 1990.

Co-Chairman, Prostaglandins in Gastroenterology: Focus on Misoprostol. Sixth International Conference on Prostaglandins and Related Compounds, Florence, Italy, June 1986.

Chairman, Cytoprotection and Acid Peptic Diseases (Symposium), European Association for Gastroenterology and Endoscopy, Berlin, Germany, 1986.

Chairman, Prostaglandins in Gastroenterology (Symposium), Chicago Society of Gastroenterology. Chicago, Illinois, 1984.

Chairman, Recent Developments in Gastrointestinal Pharmacology. ASPET Symposium, Portland, Oregon, 1979.

Chairman, Current Concepts of Gastrointestinal Motility. ASPET Symposium, Atlantic City, New Jersey, 1978.

Chairman, Gastrointestinal Pharmacology Symposium, Chicago, Illinois, 1977.

Field editor, Drug Development Research.

Edited or co-edited journal supplements and proceedings of several international symposia.

Served as a member of study group sponsored by the United States Congress, Commission on Digestive Diseases as a National Problem (1977-1978).

Scientific Reviewer for: J Pharmacol Exp Therap, Europ J Pharmacol, Digestive Diseases and Sciences, Gastroenterology, American J of Gastroenterology, Digestive Diseases, Digestion, Laboratory Investigations, Prostaglandins, Federation Proceedings, J Medicinal Chemistry, Life Sciences, J Soc Exp Biol and Medicine, Drug Development Research, American J Pathology, J Pharmacy and Pharmacology, Biochemical Pharmacology, J of the Association for Academic Minority Physicians, Oman Medical Journal, British Journal of Pharmaceutical Research, the Scientific World Journal and other journals.

Member of the editorial advisory boards for Clinical Pharmacology: Advances and Application; Journal of Physiology and Pharmacology; Drug Development Research; Journal of the Association for Academic Minority Physicians; Medical Science Monitor; British Journal of Pharmaceutical Research; WebMed (Scientific Advisory Board/Faculty).

Served on the research and international relations committees for the American College of Gastroenterology.

Served on the program committees for the European Association of Gastroenterology and Endoscopy, The Interscience World Conference on Inflammation and Chicago Biotech Network.

Research Activities/ Interests: Clinical Pharmacology and clinical development.
Gastrointestinal Pharmacology: Discovery and characterization of drugs affecting gastrointestinal defense, secretion and motility.
Central Nervous System Pharmacology: CNS drugs, narcotic analgesics, cannabinoids, alcohol and primary dependence.
Prostaglandins: Gastrointestinal, cardiopulmonary, urological and obstetrical properties.
Growth hormones (e.g., epidermal growth factor) pharmacology and toxicology.
Non-Steroidal Anti-inflammatory drugs.
Drug development and regulatory affairs.

Teaching Experience: Adjunct Professor of Medicine, Gastroenterology Section, Loyola University-Chicago, 1995-present.
Adjunct Professor of Medicine, Gastroenterology Section, King/Drew Medical Center, University of California at Los Angeles, 1984-1995.
Adjunct Professor of Pharmacology, Chicago Medical School, Chicago, Illinois, 1983-1990.
Adjunct Associate Professor of Pharmacology, Northwestern University Medical and Dental Schools, 1980-1995.
Participated in teaching pharmacology and toxicology to medical students, dental students, graduate students, residents, fellows and house staff at UCLA, Northwestern and Chicago Medical School.
Organized and chaired symposia at national and international meetings.
Supervised thesis research of postdoctoral students (Ph.D. /M.D.) and gastroenterology fellows. Pioneered the organization of the postdoctoral research program at Searle.
Served as research advisor to undergraduate medical students who worked in my laboratory at Searle Laboratories & Rohm & Hass.
Served as a guest lecturer on pharmacology and gastroenterology on many occasions, at graduate teaching institutions.
Served the American Society of Pharmacology and Experimental Therapeutics (ASPET) sponsored program entitled "Activities of Pharmacologists in the Pharmaceutical Industry" for the purpose of interesting undergraduate pharmacologists in a research career in the pharmaceutical industry.
Served as a "Visiting Professor for Minority Institutions", a program sponsored by the Federation of American Societies for Experimental Biology to promote career development in biomedical research.

**Management
Experience:**

President of IDDC Corporation, a contract research organization. The administrative responsibilities include research supervision, contract negotiations, study placements, recruiting investigators and professional employees.

Directed clinical research. Prepared and implemented worldwide clinical development plans and budgets.

Directed a large, worldwide Phase-III/IV clinical development program for the evaluation of the therapeutic and prophylactic actions of misoprostol against nonsteroidal anti-inflammatory drugs-induced ulcer.

Planned and directed the corporate anti-ulcer and anti-diarrheal research programs at Searle Laboratories.

Chaired a multi-disciplinary research team (Ph.D. /M.D. level scientists) at Searle Laboratories of senior biological, chemical, pharmaceutical and medical personnel responsible for basic and applied research on new drug candidates.

Allocated resources and evaluated performance of subordinates.

Interacted with legal, marketing, regulatory affairs and product acquisition groups at Searle Laboratories regarding currently marketed and future products.

Served as a member of the Scientific Advisory Boards of Dena Corporation, CV Pharmaceuticals and Atlantic Pharmaceuticals, Inc.

Member of the Board of Directors and Founder of the Chicago Biotech Network. (CBN).

Councilor and a member of the Board of Directors of the Association for Academic Minority Physicians (AAMP).

Publications: A. Patents

1. DeBenneville PL, Moss JN, Dajani EZ: Gastrointestinally active thiourea. US patent No. 3,950,537, April 1976.
2. Dajani EZ, Yen CH: 5-(1,1 Diphenyl-4-(cyclic amino) but-2-trans-3n-1-yl)-2-alkyl-1,3,3-oxadiazoles and intermediates thereto. US patent No. 3,996,214, December 1976.
3. Adelstein GW, Dajani EZ, Yen CH: Antidiarrheal compounds. US patent No. 3,998,832, December 1976.
4. DeBenneville PL, Moss JN, Dajani EZ: Gastrointestinally active thioureas. US patent No. 4,009,284, February 1977.
5. Adelstein GW, Dajani EZ, Yen CH: Triarylpropyl azabicyclooctanes. US patent No. 4,057,549, November 1977.
6. Adelstein GW, Dajani EZ, Yen CH: 1-Triaryl-alkyl-4-phenyl-4-piperidine carboxylic acid and derivatives. US patent No.4,066,654. January 1978.
7. Adelstein GW, Dajani EZ, Yen CH: 1-(3,3,3-Triarylalkyl)-4-phenylpiperidinealkanols. US patent No. 4,072,686. February 1978.
8. Adelstein GW, Dajani EZ, Yen CH: Novel antidiarrheal 4-azatricyclo [4.3.1.1] undecane derivatives. US patent No. 4,086,227, April 1978.
9. Dajani EZ: Method for cholesterol lowering. US patent No. 4,459,310. July 1984.
10. Spilburg, CA, Lange LG, Dajani EZ: Method for treating ulcers with sulfated polysaccharides. US Patent No. 5,679,375, October 1997.

Publications: B. Books and Chapters

1. Moss JN, Dajani EZ: Antihyperlipidemic agents. In: *Screening Methods in Pharmacology*, Vol. 2. Eds. Turner RA, Hebborn P, Acad. Press, NY, PP 121-143, 1971.
2. Dajani EZ: The actions of prostaglandins on the gastrointestinal tract. In: *Prostaglandins in the Upper Gastrointestinal Tract*. Vol. 5, in Therapeutics Today Series, Addis Press, Australasia Pty., Ltd., PP 9-18, 1986.
3. Dajani EZ: Mucosal protective activities of misoprostol in man: An overview. In: *Gastrointestinal Cytoprotection by Prostaglandins: Focus on Misoprostol*. Eds. Bianchi Porro G, Dajani EZ, Cortina International-Verona, Italy. PP 21-32, 1987.
4. Dajani EZ, Wehrschütz E: Prostaglandins and the integrity of the gastrointestinal mucosa. In: *Erosionen in Magen und Duodenum*. Eds. Van Maercke Y, Bergemann W. VCH Publishers, New York, NY, PP 211-216, 1987.
5. Dajani EZ: Perspectives on the pharmacology of misoprostol. In: *Ulcer Disease: New Aspects of Pathogenesis and Pharmacology*. Eds. Szabo S, Pfeifer C. CRC Press, Boca Raton, Florida, Chapter 27, PP 321-334, 1989.
6. Dajani EZ, Gallo-Torres H: Pharmaceutical industry perspective of the human investigation of peptic ulcer disease. In: *Ulcer Disease: Investigation and Basis for Therapy*. Eds. Szabo S, Swabb E, Marcel Dekker, New York, PP 459-485, 1991.
7. Dajani EZ: Prostaglandins and esophageal mucosal integrity. In: *Advances in Drug Therapy of Gastroesophageal Reflux Disease*. Ed. Scarpignato E, Karger, Basel PP 307-316, 1992.
8. Dajani EZ, Agrawal NM: Prevention and treatment of gastric and duodenal ulcers induced by nonsteroidal anti-inflammatory drugs. In: *NSAIDs - Mechanisms and Clinical Use*. Eds. Lewis AJ, Furst D, Marcel Dekker, New York, PP 159-170, 1994.
9. Agrawal NM, Dajani EZ: Drug-induced ulcers. In: *Gastrointestinal Pharmacology and Therapeutics*. Eds. Friedman J, Jacobson ED, McCallum R, Lippincott-Raven Publishers, Hagerstown, Maryland, Chapter 5, PP 55-63, 1997.
10. Dajani EZ, Dajani NE, Shahwan TG: Over-the-Counter Drugs. In: *Encyclopedia of Gastroenterology*. Ed. Johnson LR, Elsevier Science., PP 16-23, 2004.

Publications: C. Research Papers

1. Dajani EZ: Studies on the toxicology and central nervous system pharmacology of ethylene glycol monomethyl ether in rats and mice. Unpublished Ph.D. thesis, Purdue University, 1968.
2. Dajani EZ, Driskill DR, Bianchi RG, Collins PW: Comparative gastric antisecretory and antiulcer effects of Prostaglandin E₁ and its methyl ester in animals. *Prostaglandins* 10:205-216, 1975.
3. Dajani EZ, Driskill DR, Bianchi RG, Collins PW, Pappo R: Influence of the position of the side chain hydroxyl group on the gastric antisecretory and anti-ulcer actions of E₁ prostaglandin analogs. *Prostaglandins* 10:733-745, 1975.
4. Sanvordeker DR, Dajani EZ: In-vitro adsorption of diphenoxylate hydrochloride on activated charcoal and its relationship to pharmacological effects of the drug in-vivo. *J Pharm Sci* 64:1877-1879, 1975.
5. Dajani EZ, Roge EAW, Bertermann RE: Effects of E-prostaglandins, diphenoxylate and morphine on intestinal motility in vivo. *Europ J Pharmacol* 34:105-113, 1975.
6. Collins PW, Dajani EZ, Bruhn MS, Brown CH, Palmer JR, Pappo R: Influence of the position of the side chain hydroxyl group on the biological properties of prostaglandins. *Tetrahedron Letters* 48:4217-4220, 1975.
7. Bruhn M, Brown CH, Collins PW, Palmer JR, Dajani EZ, Pappo R: Synthesis and properties of 16-hydroxy analogs of PGE₂. *Tetrahedron Letters* 4:235-238, 1976.
8. Dajani EZ, Callison DA, Bianchi RG, Driskill DR: Gastric antisecretory effects of E-prostaglandins in rhesus monkeys. *Dig Dis and Sci* 21:1020-1028, 1976.
9. Dajani EZ, Callison DA: Gastric antisecretory actions of 15(S) 15-methyl prostaglandin E₂ methyl ester and natural prostaglandin E₂ in rhesus monkeys. *Prostaglandins* 11:799-808, 1976.
10. Dajani EZ, Driskill DR, Bianchi RG, Collins PW, Pappo R: SC-29333, a potent inhibitor of canine gastric secretion. *Dig Dis Sci* 21:1049-1057, 1976.
11. Mackerer CR, Clay GA, Dajani EZ: Loperamide binding to opiate receptor sites of brain and myenteric plexus. *J Pharmacol Exp Therap* 199:131-140, 1976.
12. Dajani EZ, Rozek LF, Sanner JH, Miyano M: Synthesis and biological evaluation of W-homologues of prostaglandin E₁. *J Med Chem* 19:1007-1010, 1976.

13. Adelstein GW, Yen CH, Dajani EZ, Bianchi RG: 3,3-Diphenyl-3 (2-alkyl-1,3,4-Oxadiazol-5-yl) propylcycloalkylamines: A novel series of anti-diarrheal agents. *J Med Chem* 19:1221-1225, 1976.
14. Dajani EZ, Bianchi RG, East PF, Bloss JL, Adelstein GW, Yen CH: The pharmacology of SC-27166: A novel anti-diarrheal agent. *J Pharmacol Exp Therap* 203:512-526, 1977.
15. Dajani EZ, Driskill DR: Effects of 7-oxa-13-prostynoic acid (7-OPyA) and prostaglandin E₁ methyl ester on canine gastric secretion. *Prostaglandins* 14:659-665, 1977.
16. Collins PW, Dajani EZ, Driskill DR, Bruhn MS, Jung CJ, Pappo R: Synthesis and gastric antisecretory properties of 15-deoxy, 16-hydroxy E-prostaglandin analogs. *J Med Chem* 20:1152-1159, 1977.
17. Mackerer CR, Brougham LR, East PF, Bloss JL, Dajani EZ, Clay GA: The binding of SC-27166 [2-[3,3-diphenyl-3-(2-methyl-1,3,4-oxadiazol-5-yl)propyl]-azabicyclo [2.2.2] Octane], a new antidiarrheal agent, to opiate receptor sites of brain and myenteric plexus. *J Pharmacol Exp Therap* 203:527-538, 1977.
18. Dajani EZ, Callison DA, Bertermann RE: Effects of E-prostaglandins on canine gastric potential difference. *Dig Dis Sci* 23:436-442, 1978.
19. Dajani EZ, Callison DA, Bianchi RG: Gastric antisecretory effects of propantheline bromide and metiamide in rhesus monkeys. *Arch Int Pharmacodyn Therap* 234:107-117, 1978.
20. Dajani EZ, Driskill D: Effect of oral and intravenous propantheline bromide on pentagastrin-stimulated canine gastric secretion. *Arch Int Pharmacodyn Therap* 233:243-250, 1978.
21. Colton DG, Driskill DR, Phillips EL, Poy P, Dajani EZ: Effect of SC-29333, an inhibitor of gastric secretion, on canine gastric mucosal blood flow and serum gastrin levels. *Arch Int Pharmacodyn et Therap* 236:86-95, 1978.
22. Dajani EZ, Bertermann, RE, Roge EAW, Schweingruber FL, Woods EM: Canine gastrointestinal motility effects of prostaglandin F₂ alpha in vivo. *Arch Int Pharmacodyn Therap* 237:16-24, 1979.
23. Dajani EZ, Bianchi RG, Calhoun DW: Synergistic actions of propantheline bromide with cimetidine and thiopropazate hydrochloride in the prevention of stress ulcer formation in rats. *J Pharmacol Exp Therap* 210:373-377, 1979.
24. Colton DG, Callison DA, Dajani EZ: Effects of prostaglandin E₁ derivative, SC-29333, and aspirin on gastric ionic fluxes and potential difference in dogs. *J Pharmacol Exp Therap* 210:283-288, 1979.

25. Dajani EZ, Woods EM, Roge EAW, Bertermann RE, Schweingruber FL: Naloxone reversal of drug-induced diarrhea in mice. *Arch Int Pharmacodyn Therap* 240:340-350, 1979.
26. Dajani EZ, Bianchi RG, Casler JJ, Weet JF: Gastric antiulcer and antisecretory effect of carbenoxolone, aldosterone and desoxycorticosterone in rats. *Arch Int Pharmacodyn Therap* 242:128-138, 1979.
27. Gullikson GW, Dajani EZ, Bianchi RG: Inhibition of intestinal secretion in the dog: A new approach for the management of diarrheal states. *J Pharmacol Exp Therap* 219: 591-597, 1981.
28. Dajani EZ, Driskill DR, Bianchi RG, Phillips EL, Woods EM, Colton DG, Collins PW, Pappo R: Effect of prostaglandin analogue, SC-30249, on canine gastric secretion. *Drug Dev Res* 3:339-347, 1983.
29. Collins PW, Dajani EZ, Pappo R, Gasiecki AF, Bianchi RG, Woods EM: Synthesis and gastric antisecretory properties of 4,5 unsaturated derivatives of 15-deoxy-16-hydroxy-16-methyl prostaglandin E₁. *J Med Chem* 26:786-790, 1983.
30. Dajani EZ, Nissen CA: Investigations of the gastrointestinal cytoprotective effects of misoprostol: Clinical efficacy overview. *Dig Dis Sci* 30:194S-200S, 1985.
31. Collins PW, Pappo R, Dajani EZ: Chemistry and synthetic development of misoprostol. *Dig Dis Sci* 30:114S-117S, 1985.
32. Sontag SJ, Mazure PA, Pontes JF, Beker SG, Dajani EZ: Misoprostol in the treatment of duodenal ulcer: A multi-center, double-blind, placebo-controlled study. *Dig Dis and Sci* 30:159S-163S, 1985.
33. Agrawal NM, Saffouri B, Kruss DM, Callison DA, Dajani EZ: Healing benign gastric ulcer: A placebo-controlled comparison of two misoprostol dosage regimens. A synthetic analog of prostaglandin E₁. *Dig Dis Sci* 30:164S-170S, 1985.
34. McGuigan JE, Chang Y, Dajani EZ: Effect of misoprostol, an antiulcer prostaglandin, on serum gastrin in patients with duodenal ulcer. *Dig Dis Sci* 31:120S-125S, 1986.
35. Dajani EZ: Is peptic ulcer a prostaglandin deficiency disease? An editorial. *Human Pathology* 17:106-107, 1986.
36. Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Cytoprotection against ethanol-induced gastric mucosal damage by a synthetic prostaglandin: A double-blind, endoscopic study in human subjects. *Gastrointestinal Endoscopy* 32:67-70, 1986.

37. Dajani EZ: Prostaglandins, ASA and mucosal damage. *Arzneim Forsch/Drug Research* 36:1150-1151, 1986.
38. Gullikson GW, Anglin C, Kessler L, Smeach S, Bauer R, Dajani EZ: Misoprostol attenuates aspirin-induced changes in potential difference and associated damage in canine Heidenhain pouches. *Clinical Invest Med.* 10: 145-151, 1987.
39. Bertaccini G, Dajani E, Paoletti R, Watkinson G: Prostaglandins in gastroenterology--Focus on Misoprostol--Forward. *Prostaglandins* 33 (Suppl.): 1, 1987.
40. Dajani EZ: Perspective on the gastric antisecretory effects of misoprostol in man. *Prostaglandins* 33 (Suppl.): 68-77, 1987.
41. Reimann HJ, Lewin T, Schmidt U, Wendt P, Blueml G, Dajani EZ: Misoprostol prevents damage to the gastric mucosa by stabilizing the mast cells. *Prostaglandins* 33 (Suppl.):105-116, 1987.
42. Dajani EZ: Overview of the mucosal protective effects of misoprostol in man. *Prostaglandins* 33 (Suppl.):117-129, 1987.
43. Godiwala T, Agrawal NM, Groot K, Arimura, Dajani EZ: Is cytoprotection by misoprostol against ethanol-induced gastric mucosal injury in man mediated by somatostatin? *Prostaglandins* 33 (Suppl.):130-131, 1987.
44. Davis GR, Fordtran JS, Dajani EZ: Dose-response, meal-stimulated gastric antisecretory study of prostaglandin E₁ analog, misoprostol, in man. *Dig Dis Sci* 33:298-302, 1988.
45. Agrawal NM, Godiwala T, Arimura A, Groot K, Dajani EZ: Protective effects against alcohol insult: Does somatostatin play any role? *Post Graduate Medical Journal* 64 (Suppl. 1):15-18, 1988.
46. Dajani EZ: Prostaglandins: Pharmacology, mechanism and applications in peptic ulcer disease. *Chinese J Clin Pharmacol* 5 (2):102-117, 1989.
47. Dajani EZ, Agrawal NM: Protective and therapeutic effects of prostaglandins. *Clin Pharmacol Res* 9(6): 359-369, 1989.
48. Agrawal NM, Dajani EZ: Treatment and prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. *Clin Pharmacol Res* 9 (6): 347-357, 1989
49. Dajani EZ: Mucosal defense and concept of cytoprotection. An Editorial. *Modern Pathology* 3:3-4, 1990.
50. Agrawal NM, Dajani EZ: Options in the treatment and prevention of NSAID-induced gastroduodenal mucosal damage. *J Rheumatology* 17 (Suppl): 7-11, 1990.

51. Dajani EZ, Agrawal NM: Nonsteroidal anti-inflammatory drug-induced gastrointestinal damage in the elderly: Pathogenesis and therapeutic considerations. *Internal Medicine for the Specialist* 11 (9): 91-110, 1990.
52. Dajani EZ, Wilson DM, Agrawal NM: Prostaglandins: An overview of the worldwide clinical experience. *J Assoc Acad Min Physicians* 2:23-25, 1991.
53. Dajani EZ, Penin VA, Sokolov LK, Vahtangishvilli R, Bogdanov A, Afonskaya N, Ivanishvilli L, Zharova Y., Efremova I: Misoprostol and dalargin for the in-patient treatment of duodenal ulcer in the U.S.S.R. *J Assoc Acad Min Physicians* 2:18-22, 1991.
54. Dajani EZ: Review of book entitled "Clinical Investigation of gastric function." *Gastroenterology* 100:1478-1479, 1991.
55. Agrawal NM, Patel R, Mahatma M, Dajani EZ: Nonsteroidal anti-inflammatory drugs and acute upper gastrointestinal bleeding: A prospective study. *J Assoc Acad Min Physicians* 2:64-66, 1991.
56. Dajani EZ: Misoprostol: Pharmacology, pharmacokinetics and mechanisms of action. *Experimental and Clinical Gastroenterology* 1:97-106, 1991.
57. Mahatma M, Agrawal N, Dajani EZ, Nelson S, Nakamura C, Sitton J: Misoprostol but not antacid prevents endotoxin-induced gastric mucosal injury: Role of tumor necrosis factor-alpha. *Dig Dis Sci* 36: 1562-1568, 1991.
58. Dajani EZ, Straus E: Editorial Overview. In: *Updates in Acid Peptic Disorders*. Eds. Dajani EZ, Straus EW: A special edition of the *J Assoc Academic Minority Physicians* 3: 69, 1992.
59. Dajani EZ, Trotman BW: Drugs for the treatment of peptic ulcers. In: *Updates in Acid Peptic Disorders*. Eds. Dajani EZ, Straus EW: A special edition of the *J Assoc Academic Minority Physicians* 3: 78-88, 1992.
60. Arakawa T, Kobayashi K, Dajani EZ: Refractory peptic ulcers. In: *Updates in Acid Peptic Disorders*. Eds. Dajani EZ, Straus EW: A Special edition of the *J Assoc for Academic Minority Physicians* 3: 95-102, 1992.
61. Agrawal NW, Dajani EZ: Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs. *J Assoc Acad Minority Physicians* 3: 142-148, 1992.
62. Larsen KR, Dajani EZ, Ives MM: Anti-ulcer drugs and gastric mucosal injury: Effects of misoprostol, 16, 16-dimethyl PGE2 and cimetidine on hemodynamic and metabolic rate in the canine gastric mucosa. *Dig Dis Sci* 37: 1029-1038, 1992.

63. Dajani EZ, Wang B, Pei Y, Pan G, Chen S, Zheng Z, Li Y, Zhu W, Wang J, Yuan S, Yu Y, Yao ZJ: Misoprostol in the treatment of duodenal ulcers in the People's Republic of China: A comparative, double-blind multicenter study. *Drug Development Research* 27: 415-423, 1992.
64. Dajani EZ: Omega-3 fatty acids and bowel cancer. *Gastroenterology* 104:1239-1240, 1993.
65. Dajani EZ: Future treatment of peptic ulcer: Is there room for the anti-infective drugs? An editorial. *J Physiology and Pharmacology* 44: 3-6, 1993.
66. Juhl CO, Vinter-Jensen L, Jensen LS, Nexø E, Djurhuus JC, Dajani EZ: Systemic treatment with recombinant human epidermal growth factor accelerates healing of sclerotherapy-induced esophageal ulcers and prevents esophageal stricture formations in pigs. *Dig Dis Sci* 39: 2671-2678, 1994.
67. Juhl CO, Vinter-Jensen L, Jensen LS, Nexø E, Djurhuus JC, Dajani EZ: Biomechanical properties of the oesophagus damaged by sclerotherapy: An impedance planimetric study in minipigs. *Scand J Gastroenterol* 29: 867-873, 1994.
68. Vinter-Jensen L, Frokiaer J, Jorgensen PE, Marqversen J, Rehling M, Dajani EZ, Nexø E: Tissue distribution of ¹³¹I-labelled epidermal growth factor in pig visualized by dynamic scintigraphy. *J Endocrinology* 144: 5-12, 1995.
69. Dajani EZ, Agrawal NM: Prevention on nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: Role of mucosal protective and gastric anti-secretory drugs. *Digestive Diseases* 12 (Suppl 1): 46-61, 1995.
70. Dajani EZ, Agrawal NM: Prevention and treatment of NSAID-induced ulcers: An update. *J Physiol Pharmacol* 46: 3-16, 1995.
71. Vinter-Jensen L, Juhl CO, Eika B, Gregersen H, Dajani EZ: Epidermal growth factor attenuates the sclerotherapy associated biomechanical properties of the oesophagus: An experimental study in minipigs. *Scand J Gastroenterol* 30: 614-619, 1995.
72. Vinter-Jensen L, Juhl CO, Rehfeld JF, Poulsen SS, Dajani EZ, Nexø E: Chronic treatment with epidermal growth factor induces hypergastrinemia in pigs. *Scand J Gastroenterol* 30: 422-427, 1995.
73. Vinter-Jensen L, Juhl CO, Djurhuus JC, Dajani EZ, Teglbjaerg PS, Uvelius, Nexø E: Ureteric growth in Gottingen minipig induced by epidermal growth factor. A case report. *Scand J Urol Nephrol Suppl* 172: 109-115, 1995.

74. Juhl CO, Vinter-Jensen L, Jensen LS, Dajani EZ, Nexø E: Preventive effects of recombinant human epidermal growth factor on the esophageal epithelium in pigs subjected to sclerotherapy. *Europ J Hepatol Gastroenterol* 17: 823-828, 1995.
75. Vinter-Jensen L, Juhl CO, Djurhuus JC, Poulsen SS, Dajani EZ, Brown KD, Orntoft TF, Teglbjærg PS, Nexø E: Chronic Systemic treatment with epidermal growth factor in pigs causes pronounced urothelial growth with accumulation of glycoconjugates. *Am J Pathol* 147: 1330-1338, 1995.
76. Juhl CO, Vinter-Jensen L, Myhre-Jensen O, Jensen LS, Dajani EZ: Systemic treatment with epidermal growth factor in pigs induces anemia in Gottingen pigs. *Clinical Sciences* 89: 453-458, 1995.
77. Vinter-Jensen L, Juhl CO, Poulsen SS, Djurhuus JC, Dajani EZ, Nexø E: Chronic administration of epidermal growth factor to pigs induces growth especially of the urinary tract with accumulation of epithelial glycoconjugates. *Lab Invest* 73: 788-793, 1995.
78. Juhl CO, Vinter-Jensen L, Poulsen SS, Orntoft TF, Dajani EZ: Chronic treatment with epidermal growth factor causes esophageal hyperplasia in pigs and rats. *Dig Dis Sci* 40: 2717-2723, 1995.
79. Dajani EZ: Prostaglandins, NSAIDs and gastrointestinal mucosal injury: Can we identify patients at risk of NSAID-induced gastric injury? An Editorial. *Am J Gastroenterol* 91 (5): 835-836, 1996.
80. Vega KJ, Bollu J, Dajani EZ, Trotman BW: Idiopathic esophageal ulceration in HIV patients. *J Assoc Acad Min Phys* 74 (4): 93-98, 1996.
81. Vinter-Jensen L, Juhl CO, Frystyk J, Dajani EZ, Oksbjerg N, Flyvbjerg N: The effects of epidermal growth factor (EGF) on circulating levels on insulin like growth factor I(IGF-I) and IGF binding proteins (IGFBPs) in adult Goettingen minipigs. *J Endocrinol* 151: 401-407, 1996.
82. Gregersen H, Vinter-Jensen L, Juhl CO, Dajani EZ: Impedance planimetric characterization of distal esophagus in the Goettingen minipigs. *J Biomech* 29: 63-68, 1996.
83. Vinter-Jensen L, Juhl CO, Dajani EZ, Nielsen M, Djurhuus JC: Chronic systemic treatment with epidermal growth factor induces smooth muscle cell hyperplasia and hypertrophy in the urinary tract of mature Goettingen minipigs. *British J Urology* 79: 532-538, 1997.
84. Vinter-Jensen L, Juhl CO, Teglbjærg PS, Poulsen SS, Dajani EZ, Nexø E: Systemic treatment with epidermal growth factor in pigs induces ductal proliferations in the pancreas. *Gastroenterology* 113: 1367-1374, 1997.

85. Dajani EZ: Gastrointestinal Toxicity of over-the-counter analgesics. An Editorial. *Am J Gastroenterol* 93(7): 1020-1022, 1998.
86. Larsen KR, Dajani EZ, Dajani NE, Dayton MT, Moore JG: Effects of tolcapone, a catechol-o-methyl transferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs. *Dig Dis Sci* 43(8): 1806-1813, 1998.
87. Adeoti AG, Vega KJ, Dajani EZ, Trotman BW, Kloser PC: Idiopathic esophageal ulcerations in HIV infected patients. Successful treatment with misoprostol and viscous Lidocaine. *Am J Gastroenterol* 93(11): 2069-2074, 1998.
88. Dajani EZ, Larsen KR, Taylor J, Dajani NE, Shahwan TG, Neeleman SD, Taylor MS, Dayton MT, Mir GN: CT-3 [1'1'-dimethyl-heptyl-Delta-8-THC-11-oic acid]: A novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. *J Pharmacol Exp Therap* 291: 31-38, 1999.
89. Dajani EZ: Gastroesophageal reflux disease (GERD): Pathophysiological and pharmacological considerations. *J Assoc Acad Minority Physicians* 11: 7-11, 2000.
90. Trotman BW, Boyce JG, Dajani EZ, Kamholz SL, Rayford PL, Scott VF: Highlights of the 13th Annual Scientific Meeting of the Association for Academic Minority Physicians. *J Assoc Acad Minority Physicians* 11: 3-5, 2000.
91. Dajani EZ, Klamut M: Therapeutic approaches for gastric and duodenal ulcers: An update. *Expert Opinion on Investigational Drugs* 90: 1537-1544, 2000.
92. Dajani EZ, Agrawal NM: Selective COX-2 inhibitors and gastrointestinal mucosal injury: Pharmacological and therapeutic considerations. *J Assoc Acad Minority Physicians* 11: 28-31, 2000.
93. Trotman BW, Boyce JG, Dajani EZ, Davidson EC, Scott VF: Highlights of the 14th Annual Scientific Meeting of the Association for Academic Minority Physicians, 2000. *J Assoc Acad Minority Physicians* 12: 95-97, 2001.
94. Dajani EZ, Shahwan TG, Dajani, NE: Statins, platelets aggregation and coronary heart disease. *J Assoc Acad Minority Physicians* 13: 27-31, 2002.
95. Trotman BW, Scott VF, Dajani EZ, Davidson EC, Kamholz SL: Highlights of the 15th Annual Scientific Meeting of the Association for Academic Minority Physicians, 2001. *J Assoc Acad Minority Physicians* 13: 6-8, 2002.
96. Dajani EZ, Shahwan TG, Dajani, NE: Prostaglandins and the Brain-Gut Axis. *J Physiology and Pharmacology* 54: 155-164, 2003.

97. Konturek, SJ, Pawlik WW, Dajani EZ: Brain-Gut Axis in gastrointestinal system: Introductory Remarks. *J Physiology and Pharmacology* 54: 3-8, 2003.
98. Dajani EZ, Dajani ME: Are U.S. cosmetic regulatory policies keeping consumers safe? Update (Published by Food and Drug Laws Institute) 6: (November/December): 22-24, 2005.
99. Dajani EZ, Islam K: Cardiovascular and gastrointestinal toxicity of selective cyclooxygenase-2 inhibitors. *J Physiol Pharmacol* 59 (supplement 2): 117-33, 2008.
100. Dajani E Z: Biochemical and biophysical models of constipation and diarrhea [Review of the article 'Biochemical and Biophysical Models of Constipation and Diarrhea Caused by Incorrect Dose or Uneven Intake of Edible Oils (Fats) by Zou C]. *WebMed Central* 2014;5(8):WMCRW003095.
101. Dajani EZ: How do Antidepressants Act; What Are Their Adverse Effects; and What Harm is Associated with These Drugs? Published in *Medical Law Perspectives*. Wordsworth Law Publications, Inc. New York, NY. December 2014.

Abstracts/Presentations:

1. Dajani EZ: Studies on the pharmacology of the industrial solvent methyl cellosolve. Society of Experimental Biology and Medicine. Indianapolis, Indiana. October 1968.
2. Dajani EZ, Mennear JH: Gas chromatographic assay for ethylene glycol monomethyl ester. *Toxicol Appl Pharmacol* 14(3): 618, 1969.
3. Dajani EZ: Experimental cholelithiasis: Studies on the mouse and hamster gallstone models. An invited lecture presented at the Gastrointestinal Pharmacology Group Symposium on Bile. Philadelphia, Pennsylvania. November 1970.
4. Dajani EZ: The technicians' role in toxicological studies. An invited lecture presented at the AALAS Symposium on Laboratory Animal Considerations in Toxicology and Related Disciplines. New Brunswick, New Jersey. June 1972.
5. Dajani EZ: Gastric antisecretory and antiulcer actions of E-prostaglandin analogs. An invited lecture presented at the Department of Medicine (Gastroenterology), University of California, San Francisco, California. April 1974.
6. Dajani EZ, Roge EAW, Bertermann RE: The effect of prostaglandin E₁ methyl ester and diphenoxylate on canine duodenal motility in-vivo. Presented at the Midwest Pharmacology Meeting. Ann Arbor, Michigan. May 1975.
7. Dajani EZ, Driskill DR, Bianchi RG, Collins PW, Pappo R: Studies on the biological properties of a prostaglandin analog, SC-29333, a potent inhibitor of gastric secretion. Presented at the International Conference on Prostaglandins. Florence, Italy. May 1975.
8. Collins PW, Pappo R, Dajani EZ: Application of 1,4 addition reactions to the synthesis of novel prostaglandins. Presented at the International Conference on Prostaglandins. Florence, Italy. May 1975.
9. Dajani EZ, Bianchi RG, Adelstein GW, Yen CH: Studies on the biological properties of SC-27166, a novel antidiarrheal agent. Philadelphia GI Research Forum. Philadelphia, Pennsylvania. October 1975.
10. Dajani EZ, Driskill DR, Bianchi RG, Collins PW, Pappo R: Studies on the pharmacology of SC-29333, a potent gastric antisecretory prostaglandin. Philadelphia GI Research Forum. Philadelphia, Pennsylvania. October 1975.
11. Adelstein GW, Yen CH, Dajani EZ: Synthesis and biology of a novel series of antidiarrheal agents. Am Chem Soc Meeting. Mexico City, Mexico, 1975.

12. Pappo R, Collins PW, Bruhn MS, Palmer JR, Dajani EZ: Synthesis and biological properties of 16-hydroxy prostaglandin analogs. Winter Prostaglandin Conference. Vail, Colorado. January 1976.
13. Dajani EZ, Callison DA, Bianchi RG, Driskill DR: Gastric antisecretory effects of E-prostaglandins in conscious monkeys. *Federation Proceedings* 35: 539, 1976.
14. Dajani EZ: Effects of E-prostaglandins on the gastric mucosal barrier. An invited presentation at the Gastrointestinal Pharmacology Symposium entitled "Drugs and the Gastric Mucosal Barrier." Groton, Connecticut. October 1976.
15. Callison DA, Dajani EZ, Bertermann RE: Effects of E-prostaglandins on canine gastric potential differences. *Federation Proceedings* 36:595, 1977.
16. Dajani EZ: Drug research in the pharmaceutical industry: A pharmacologist's point of view. An invited series of continuing medical and pharmaceutical education lectures presented at the Kuwait Ministry of Health, Kuwait. November 1977.
17. Driskill DR, Colton DG, Phillips EL, Poy P, Dajani EZ: Effect of SC-29333 on gastric mucosal blood flow and serum gastrin in the dog. *Federation Proceedings* 37: 459, 1978.
18. Callison DA, Dajani EZ, Bianchi RG: Gastric antisecretory actions of propantheline bromide and metiamide in conscious rhesus monkeys. *Federation Proceedings* 37: 460, 1978.
19. Dajani EZ: Perspective on the pharmacology of antidiarrheal drugs. An invited presentation at a 1978 ASPET Symposium entitled "Current Concepts of Gastrointestinal Motility." Atlantic City, New Jersey. April 1978.
20. Dajani EZ, Roge EAW, Bertermann RE, Schweingruber FL: Gastrointestinal motility effects of PGF₂ alpha in the dog. 7th International Congress of Pharmacology. Paris, France. July 1978.
21. Dajani EZ, Roge EW, Bertermann RE, Schweingruber FL: Reversal of gastrointestinal motility actions of PGF₂ alpha by naloxone. 7th International Congress of Pharmacology. Paris, France. July 1978.
22. Bianchi RG, Dajani EZ, Calhoun DW: Synergistic actions of propantheline bromide, cimetidine and thiopropazate in the prevention of stress ulcer formation in rats. *Pharmacologist* 20:209, 1978.
23. Dajani EZ: Pharmacology of anti-cholinergic drugs. Invited lecture presented at The Northern Illinois Orthodontic Study Group. Chicago, Illinois. October 1978.

24. Adelstein GW, Yen CH, Dajani EZ, Bianchi RG: Potent analogs of Lomotil; separation of constipating and analgesic properties. Amer Chem Soc Great Lakes Regional Meeting. Rockford, Illinois. June 1979.
25. Dajani EZ: Perspective on the pharmacology of gastric antisecretory and antiulcer drugs. An invited lecture presented at the Amer Chem Soc Symposium on Peptic Ulcer, Great Lakes Regional Meeting. Rockford, Illinois. June 1979.
26. Woods EM, Dajani EZ, Roge EW, Bertermann RE, Schweingruber FL: Naloxone reversal of drug-induced diarrhea in mice. *Pharmacologist* 21:175, 1979.
27. Dajani EZ, Bianchi RG, Casler JJ, Weet JF: Gastric antiulcer and antisecretory effects of carbenoxolone, aldosterone and desoxycorticosterone in rats. *Pharmacologist* 21:176, 1979.
28. Bianchi RG, Dajani EZ, Casler JJ, Calhoun DW: Synergistic actions of propantheline bromide with cimetidine and thiopropazate hydrochloride in the inhibition of gastric secretion in rats. *Pharmacologist* 21:176, 1979.
29. Dajani EZ: Prostaglandins and the gut: An update. An invited lecture presented at the ASPET Symposium entitled "Recent Developments in Gastrointestinal Pharmacology." Portland, Oregon. 1979.
30. Dajani EZ: Perspective on the pharmacology of antiulcer drugs: An update. Grand Rounds presented at the Department of Medicine, Northwestern University. Chicago, Illinois. November 1979.
31. Driskill DR, Dajani EZ, Phillips EL, Collins PW, Pappo R: Effects of a prostaglandin analogue, SC-30249, on canine gastric secretion. *Federation Proceedings* 39(3): 563, 1980.
32. Dajani EZ: Comparison between the pharmacology of gastric and duodenal antiulcer drugs. An invited presentation at a symposium entitled "Duodenal and Gastric Ulcers - Pathogenesis and Pharmacology," co-sponsored by Society of Pathology and ASPET. Anaheim, California. April 1980.
33. Bianchi RG, Dajani EZ, Casler JJ: Gastric antiulcer and antisecretory effects of bismuth salts in the rat. *Pharmacologist* 22:168, 1980.
34. Gullikson GW, Dajani EZ, Bianchi RG: Reversal of deoxycholate-induced intestinal fluid secretion by lidamidine. *Pharmacologist* 22:168, 1980.
35. Yen CH, Bianchi RG, Dajani EZ: Synthesis and biological activities of substituted quinuclidines. Amer Chem Soc Meeting. Chicago, Illinois. January 1981.

36. Dajani EZ: Pharmacology of the prostaglandin analogue SC-29333. International Congress on Stomach Diseases, University of Antwerp. Antwerp, Belgium. May 1981.
37. Dajani EZ: Prostaglandins and the gastrointestinal tract. Grand Rounds, Hines VA Hospital. Hines, Illinois. May 1981.
38. Kessler L, Bianchi RG, Callison DA, Dajani EZ: Prevention of duodenal ulcer formation in the cat by E-prostaglandins. *Pharmacologist* 23:121, 1981.
39. Bianchi RG, Casler JJ, Dajani EZ: Gastric antisecretory and antiulcer activity of SC-29333: A synthetic E-prostaglandin analog. *Pharmacologist* 23:121, 1981.
40. Gullikson GW, Jasty V, Dajani EZ: Effect of lidamide on deoxycholate-induced histological and permeability changes in canine jejunum. *Pharmacologist* 23:122, 1981.
41. Dajani EZ: Perspectives on the pharmacology of antiulcer drugs. An invited lecture presented at a symposium entitled "Recent Advances Against Duodenal and Gastric Ulcer Disease," 13th Lithuanian American Medical Association. Chicago, Illinois. September 1981.
42. Collins PW, Dajani EZ, Pappo R, Gasiecki AF, Bianchi RG, Woods EM: Synthesis and gastric antisecretory properties of 4,5-unsaturated derivatives of 15-deoxy-16-hydroxyl-16-methyl prostaglandin E₁. *Amer Chem Soc* 183:62, 1982.
43. Pitzele BS, Kellar P, Kessler L, Sanner J, Woods EM, Dajani EZ: Quaternary ammonium analogs of an H₂-receptor antagonist. *Amer Chem Soc* 183: 58, 1982.
44. Dajani EZ: Perspectives on the pharmacology of misoprostol, a synthetic PGE₁ analogue. An invited lecture presented at the Gordon Research Conference on Medicinal Chemistry, Colby-Sawyer College. New London, New Hampshire. August 1982.
45. Dajani EZ, Collins PW, Bianchi RG, Woods EM, Colton DG, Driskill DR, Pappo R: Gastrointestinal pharmacology of misoprostol: A novel antiulcer agent. Invited lecture, Department of Pharmacology, University of Wisconsin. Madison, Wisconsin. April 1983.
46. Gullikson GW, Anglin C, Kessler L, Smeach S, Crowder S, Bauer R, Dajani EZ: Misoprostol prevents aspirin-induced damage in canine Heidenhain pouches. *Gastroenterology* 84:1176, 1983.
47. Dajani EZ: Prostaglandins. An invited presentation, Chicago Society of Gastroenterology. Chicago, Illinois. March 1984.
48. Dajani EZ: Prostaglandins in gastroenterology. An invited lecture (principal speaker), European Association for Gastro-Camera, Diagnosis and Endoscopy. Innsbruck, Austria. March 1984.

49. Collins PW, Gasiecki AF, Decktor D, Dajani EZ, Woods EM, Bianchi RG: Alpha chain unsaturated derivatives of 16-hydroxy prostaglandins. Amer Chem Soc, National Medicinal Symposium, June 1984.
50. Dajani EZ: Antidiarrheal drugs. An invited presentation delivered at a symposium entitled "Newer Gastrointestinal Drugs," sponsored by The Amer Chem Soc. Philadelphia, Pennsylvania. August 1984.
51. Tapper EJ, Dajani EZ, Polk RC: Dose-response duodenal ulcer healing by prostaglandin E₁ analog. International Congress of Gastroenterology. Lisbon, Portugal. September 1984.
52. Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Cytoprotection by prostaglandin E₁ analog on ethanol-induced gastric mucosal damage in man. Amer J Gastroenterology 79: 824, 1984.
53. Dajani EZ: Non-prostanoids as cytoprotective agents. An invited presentation, Mexican Gastroenterological Association Meeting. Guadalajara, Mexico. December 1984.
54. Dajani EZ: Mucosal cytoprotection: Clinical models. An invited presentation, Mexican Gastroenterological Association Meeting. Guadalajara, Mexico. December 1984.
55. Dajani EZ: Recent advances in the pathophysiology of peptic ulcer disease. An invited presentation, European Association for Gastroenterology and Endoscopy, 17th Congress. Berlin, West Germany. March 1985.
56. Dajani EZ, Bianchi RG, Colton DG, Callison DA, Driskill DR, Phillips EL, Kessler L, Gullikson GW, Woods EM, Collins PW, Pappo R: Perspectives on the pharmacology of misoprostol. An invited presentation, Fifth International Conference on Experimental Ulcer. Boston, Massachusetts. May 1985. Dig Dis Sci 30: 371, 1985.
57. Assad RT, Dodd DC, Dajani EZ: Effect of misoprostol, a prostaglandin E₁ analog, on epithelial proliferation of canine fundic mucosa. Gastroenterology 88: 1310, 1985.
58. Assad RT, Dodd DC, Dajani EZ: Effects of misoprostol, a prostaglandin E₁ analog, on DNA synthesis of canine fundic mucosa. Gastroenterology 88:1310, 1985.
59. Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Adaptive cytoprotection of the human gastric mucosa in response to ethanol injury. Gastroenterology 88:1496, 1985.
60. McGuigan JE, Chang Y, Deysach L, Dajani EZ: Serum gastrin in patients with duodenal ulcer treated with misoprostol. Gastroenterology 88:1496, 1985.

61. Pitzele BS, Yu SS, Hamilton RW, Moorman AE, Gullikson GW, Bianchi RG, Palicharla P, Dajani EZ: Potential antisecretory antidiarrheals, alpha-2 adrenergic agonists related to clonidine. Amer Chem Soc. Chicago, Illinois. September 1985.
62. Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Comparative cytoprotection against ethanol-induced gastric mucosal damage: Misoprostol vs. cimetidine. Amer J of Gastroenterology 80: 860, 1985.
63. Larsen KE, Dajani EZ, Muka M: Effects of misoprostol, 16, 16-dimethyl PGE₂ and cimetidine on mucosal blood flow and oxygen consumption in the dog ex vivo gastric chamber. Dig Dis Sci 31:142S, 1986.
64. Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Comparative effects against alcohol insult: Misoprostol vs. cimetidine. Dig Dis Sci 31:142S, 1986.
65. McGuigan JE, Chang Y, Dajani EZ: Effect of misoprostol, an antiulcer prostaglandin, on serum gastrin in patients with duodenal ulcer. Dig Dis Sci 31:PS120, 1986.
66. Dajani EZ: Pharmacology of misoprostol. Three lectures delivered in Birmingham, Leeds and London, U.K., as part of regional continuing medical education symposia entitled "Prostaglandins in Peptic Ulcer." February 1986.
67. Dajani EZ: Cytoprotection and acid peptic diseases. An invited presentation, European Association for Gastroenterology and Endoscopy, 18th Congress. Berlin, West Germany. March 1986.
68. Gullikson GW, Anglin C, Kessler L, Smeach S, Bauer R, Dajani EZ: Misoprostol prevents aspirin-induced changes in potential difference and associated damage in canine Heidenhain pouches. An invited presentation, Canadian Association of Gastroenterology. Toronto, Canada. April 1986.
69. Dajani EZ: The role of prostaglandins in the maintenance of mucosal integrity. An invited presentation, Canadian Association of Gastroenterology. Toronto, Canada. April 1986.
70. Dajani EZ: Prostaglandins and their actions on the gastrointestinal tract. Royal Australian College of Physicians Satellite Seminar on Prostaglandins. Hobart, Tasmania. May 1986.
71. Dajani EZ: Prostaglandins: Pharmacology, mechanisms and applications in acid peptic diseases. An invited presentation, Seventh Icelandic Congress of Internal Medicine. Reykjavik, Iceland. May 1986.

72. Dajani EZ: Perspective on the gastric antisecretory effects of misoprostol in man. Sixth International Conference on Prostaglandins and Related Compounds. Florence, Italy. June 1986.
73. Dajani EZ: Gastrointestinal cytoprotective activities of misoprostol: Clinical efficacy overview. Sixth International Conference on Prostaglandins and Related Compounds. Florence, Italy. June 1986.
74. Reimann HJ, Wendt P, Bluemel G, Schmidt U, Ohe MVD, Dajani EZ, Wehrschütz E: Misoprostol prevents damage to the gastroduodenal mucosa by stabilizing the mast cells. Sixth International Conference on Prostaglandins and Related Compounds. Florence, Italy. June 1986.
75. Dajani EZ: Clinical cytoprotective actions of misoprostol. An invited presentation, Italian Society of Gastroenterology. Verona, Italy. June 1986.
76. Dajani EZ: Prostaglandins in acid peptic disorders. An invited lecture presented at a post-graduate course sponsored by the European Society of Gastroenterology and Endoscopy. Cologne, W. Germany. October 1986.
77. Dajani EZ: Misoprostol: Pharmacology, mechanism and applications in peptic ulcer disease. An invited lecture presented at a symposium entitled "International Symposium on Cytoprotection of the Gastroduodenal Mucosa," Inter-American Society of Clinical Pharmacology and Therapeutics/Latin American Association of Pharmacology. Buenos Aires, Argentina. November 1986.
78. Dajani EZ: Overview of misoprostol clinical safety. An invited lecture presented at a symposium entitled "Prostaglandins and Peptic Ulcer Disease," Hong Kong Society of Internal Medicine. Hong Kong. December 1986.
79. Dajani EZ: Pharmacology of misoprostol: Antisecretory plus mucosal protective activity for an antiulcer agent. An invited lecture presented at the European Society of Gastroenterology and Endoscopy, Milan, Italy, June 1986. Italian Journal of Gastroenterology 19 (Suppl. 3): 19S, 1987.
80. Dajani EZ: Prostaglandins in gastroenterology. An invited presentation. Chinese Society of Gastroenterology. Kunming, People's Republic of China. November 1987.
81. Dajani EZ: Prostaglandins: An update. An invited presentation. American College of Physicians Post Graduate Course. Keystone, Colorado. February 1988.
82. Dajani EZ: Prostaglandins and NSAIDs gastropathy. An invited presentation. Pakistan Society of Gastroenterology and Gastrointestinal Endoscopy. Rawalpindi, Pakistan. March 1988.

83. Dajani EZ: Prostaglandins in gastroenterology. An invited presentation. European Society of Gastroenterology. Milan, Italy. April 1988.
84. Dajani EZ, McGuigan JE, Chang Y: Effect of the antiulcer prostaglandin misoprostol on serum gastrin in patients with duodenal ulcer. *Postgraduate Medical J* 64: 79(Abstract), 1988.
85. Dajani EZ: Prostaglandins and mucosal protection: An update. An invited presentation. Amer Association of Colleges of Pharmacy. Chicago, Illinois. July 1988.
86. Dajani EZ, Lanza F: Endoscopic comparison of the protective effects of misoprostol, cimetidine and sucralfate on nonsteroidal anti-inflammatory drugs induced gastrointestinal mucosal injury. *Endoscopy* 20: 83 (Abstract), 1988.
87. Dajani EZ: Prostaglandins and NSAIDs gastropathy. An invited presentation. 1988 International Congresses of Gastroenterology and Digestive Endoscopy. Rome, Italy. September 1988.
88. Dajani EZ: Prostaglandins. An invited presentation. The USSR Cardiology Research Center at the USSR Academy of Medical Sciences. Moscow, USSR. February 1989.
89. Dajani EZ: Protective and therapeutic effects of prostaglandins. An invited presentation given at a Symposium entitled "NSAID Damage of the Upper Gastrointestinal Tract." Third Interscience World Conference on Inflammation. Monte Carlo, Monaco. March 1989.
90. Dajani EZ: Prostaglandins and nonsteroidal anti-inflammatory drugs: Pharmacology and mechanism of action. An invited presentation. Prostaglandins Telesymposium. University of Puerto Rico. San Juan, Puerto Rico. May 1989.
91. Dajani EZ: Prostaglandins in surgical treatments. An invited presentation. Department of Surgery. Rush-Presbyterian St. Lukes Medical Center. Chicago, Illinois. June 1989.
92. Dajani EZ: Overview on the mechanisms of cytoprotection by misoprostol. An invited presentation at the International Symposium on Cell Injury and Cytoprotection. Harvard Medical School. Boston, Massachusetts. July 1989.
93. Dajani EZ: Prostaglandins and the esophagus: Pharmacological and therapeutic perspectives. An invited presentation. International Symposium on Esophageal Diseases. Taormina, Italy. September 1989.
94. Dajani EZ: Prostaglandins and nonsteroidal anti-inflammatory drugs: Pharmacology, mechanisms of action and future prospects. An invited presentation. International Symposium on Esophageal Diseases. Taormina, Italy. September 1989.

95. Dajani EZ: Prostaglandins and mucosal protection: Current and future perspectives. Visiting Professor Lecture Series, Department of Pharmacology and Toxicology. Purdue University, West Lafayette, Indiana, November 1989.
96. Downie WW, Dajani EZ: NSAID-induced gastropathy: Treatment. Second International Congress of Rheumatology. Manila, Philippines. December 1989.
97. Dajani EZ: Prostaglandins: Visiting Professor. Departments of Medicine and Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, December 1989.
98. Dajani EZ: Prostaglandins and gastroenterology. An invited presentation. Louisiana Gut Club, New Orleans, Louisiana, February 1990.
99. Dajani EZ: Prostaglandins: Current and future perspectives regarding gastric mucosal protection. American College of Physicians. Post Graduate Course, Keystone, Colorado, February 1990.
100. Dajani EZ: Historical perspectives on the discovery and development of misoprostol: A pharmacologist odyssey. An invited presentation. Second International Symposium on Experimental and New Therapeutic approaches to Ulcer Diseases. Pecs, Hungary, July 1990.
101. Dajani EZ: Pharmaceutical industry perspectives on the discovery and development of antiulcer drugs. Chairman of a Round Table Discussion. Presented at the Second International Symposium on Experimental and New Therapeutic Approaches to Ulcer Disease. Pecs, Hungary, July 1990.
102. Dajani EZ: Prostaglandins: Current and future medical developments. An invited presentation. Departments of Medicine and Surgery, Hines Veteran Administration Medical Center. Hines, Illinois, July 1990.
103. Dajani EZ: Prostaglandins: Past, present and future. An invited presentation celebrating the tenth anniversary of Donald E. Wilson, MD as a Chairman of the Department of Medicine, State University of New York, Health Science Center, Brooklyn, NY, September, 1990.
104. Agrawal NM, Dajani EZ, Stromatt S, Brown J: Misoprostol vs. sucralfate for the prophylaxis of NSAID-induced gastric mucosal damage: Result of acute and chronic administration. *Amer J Gastroenterol* 85 (9): 1228 (Abstract), 1990.
105. Dajani EZ: Prostaglandins in acid peptic disorders. An invited presentation. Second Symposium on Experimental Ulcer Disease. Otocec (Slovenia), Yugoslavia, November 1990.

106. Dajani EZ: Prostaglandins in acid peptic disorders: An overview of the worldwide clinical experience: An invited lecture. American College of Physicians Post Graduate Course, Keystone, Colorado, February 1991.
107. Agrawal NM, Stromatt S, Dajani EZ: Comparative efficacy of misoprostol and sucralfate in preventing gastric ulcers in patients on chronic NSAIDs therapy: Role of gastric erosion as a predictor for the development of ulcers. Seventh International Conference on Experimental Ulcer. Berlin, Germany, October 1991.
108. Dajani EZ, Agrawal NM: Prevention of NSAID-induced gastric damage: Effect of prostaglandins and mucosal coating compounds. Joint Meeting of the Mediterranean Society of Clinical Pharmacology and the Italian Society of Gastroenterology. Venice, Italy, October, 1991.
109. Agrawal NM, Dajani EZ: Misoprostol is superior to sucralfate in preventing NSAID-induced gastric ulcer in patients with osteoarthritis: Importance of erosions. J Association for Academic Minority Physicians 2: 179, 1991.
110. Agrawal N, Meckstroth S, Dajani EZ: Clinical significance of gastric erosions as a predictor of NSAID-induced ulcers. Gastroenterology 102:A1, 1992.
111. Dajani EZ: Clinical use of prostaglandins in ulcer therapy. An invited presentation. FASEB/AGA Summer Research Conference entitled "Molecular Basis of Gastric Mucosal Defense." Copper Mountain, Colorado, July 1992.
112. Dajani, EZ: Predictive Models For the Evaluation of Anti-ulcer and Cytoprotective Drugs in Healthy Human Subjects. An invited presentation. Italian Society of Pharmacology: Clinical Pharmacology Section, Udine, Italy, September 1993.
113. Dajani, EZ: Prostaglandins in Gastroenterology: An Update. Invited presentation. Second Osaka International Symposium on Gastroenterology. Osaka, Japan, November 1993.
114. Dajani, EZ: Prostaglandins in Medicine. Visiting Professor Lecture Series. Invited presentation. Osaka City University Medical School. Osaka, Japan, November 1993.
115. Kobayashi K, Dajani EZ, Itoh M, Arakawa T: Second Osaka International symposium on Gastroenterology: Symposium Synopsis. Dig Dis Sci 39 (4): 897-898, 1994.
116. Dajani EZ, Agrawal NM: Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs. Invited Presentation. 8th International Conference on Ulcer Research. Kyoto, Japan, November 1994. An abstract of this presentation was published in Digestion 55 (suppl 2): 7, 1994.

117. DaCosta J, Vega KJ, Trotman BW, Cunniff D, Dajani EZ: Topical misoprostol therapy for idiopathic HIV esophageal ulceration. *Am J Gastroenterol* 91: 1886, 1996.
118. Vega KJ, DaCosta J, Bollu J, Trotman BW, Kloser P, Cunnif D, Dajani EZ: Topical misoprostol therapy for HIV idiopathic esophageal ulceration: Case report and literature review. *J Association for Academic Minority Physicians* 7 (4): XXIX, 1996.
119. Dajani EZ: NSAIDs and H. pylori in peptic ulcers. Is there a connection? An invited lecture. Ministry of Public Health, Abu Dhabi, United Arab Emirates, December 1997.
120. Dajani EZ: Treatment and prevention of NSAID-induced ulcers. An invited presentation. Ministry of Public Health, Abu Dhabi, United Arab Emirates, December 1997.
121. Larsen KR, Dajani EZ, Dajani NE, Dayton MT: Effects of tolcapone and carbidopa/LDOPA on intestinal electrolyte and fluid transport in dogs. *Gastroenterology* 114: SO135, 1998.
122. Dajani EZ, Taylor J, Dajani NER, Mir GN: Investigation of the analgesic action of CT-3 [1'1'-dimethyl-heptyl-Delta-8-THC-11-oic acid] in mice: A novel, orally effective cannabinoid. *FASEB Journal* 13: A1108, 1999.
123. Dajani EZ, Larsen KR, Dajani NE, Neelman SD, Taylor MS, Dayton MT: Analgesic and ulcerogenic actions of CT-3 [1'1'-dimethyl-heptyl-Delta-8-THC-11-oic acid] in rats: A novel, orally effective cannabinoid. *FASEB Journal* 13: A1108, 1999.
124. Dajani EZ: NSAIDs, Prostaglandins and gastrointestinal mucosal defense. Invited presentation. Guilio Bertaccini Memorial Symposium, University of Parma, Parma, Italy. May 1999.
125. Dajani EZ: Regulatory considerations in the drug development process. Invited presentation. Chicago Biotech Network. Chicago, Illinois. June 1999.
126. Dajani EZ: Gastroesophageal reflux disease (GERD): Pathophysiological and pharmacological considerations. Invited speaker at a symposium entitled Gastroesophageal Reflux Disease, sponsored by the Association for Academic Minority Physicians, Washington, DC. October 1999.
127. Dajani EZ, Shahwan T, Dajani NE: Prostaglandins and brain-gut axis. Invited presentation. The Second International Symposium on Brain-Gut Axis. Basic and Clinical Aspects. Krakow, Poland. November 2003.
128. Dajani EZ, Konturek SJ: Prostaglandins and brain-gut Axis: Concluding remarks. Invited presentation. The Second International Symposium on Brain-Gut Axis. Basic and Clinical Aspects, Krakow, Poland. November 2003.

129. Dajani EZ: Pharmacological, toxicological and regulatory considerations in medical negligence. Invited presentation. The Medical Negligence Group, American Association of Justice, Vancouver, Canada. July 2010.
130. Dajani EZ: Overview of the pharmacological and therapeutic properties of Nigella Sativa seeds (black seeds): A complementary herbal drug with interesting historical, religious and clinical significance. Invited presentation. Association for Academic Minority Physicians. Naples, Florida. October 2012